Cargando…
550. Clinical impact of Tocilizumab therapy in SARS-CoV-2 respiratory infections in ICU and non-ICU patients
BACKGROUND: Tocilizumab (TCZ) is a monoclonal antibody against the interleuikin-6 receptor which is potentially beneficial in COVID-19 induced cytokine release syndrome (CRS). However, there are limited studies showing anti-inflammatory effect and clinical benefit of TCZ in COVID-19 patients. This r...
Autores principales: | Vyas, Nikunj M, Hou, Cindy, Levin, Todd P, Fussa, Mark, DeRose, Joseph, Condoluci, Mark, Williams, James, Ghayad, Zeina, Barnish, Michael, Ali, Shereef N, Kerr, Kathryn H, Scheiblein, Scott W, Fryckberg, Anthony J, Chauhan, Gauri |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777636/ http://dx.doi.org/10.1093/ofid/ofaa439.744 |
Ejemplares similares
-
1990. A Strategy of Mandatory Infectious Disease Consultations on Hospital-acquired Clostridium difficile Infection and Antimicrobial Utilization
por: Hou, Cindy, et al.
Publicado: (2019) -
575. Evaluation of Risk Factors and Clinical Outcomes of Patients with Vancomycin-Resistant Enterococcus Infections
por: Chauhan, Gauri, et al.
Publicado: (2019) -
539. Impact of Corticosteroids when Combined with Tocilizumab or Remdesivir for the Treatment of Severe SARS-CoV-2
por: Rosati, Michael, et al.
Publicado: (2021) -
Tocilizumab in ICU-admitted COVID-19 Patients: A Retrospective Study
por: Siami, Zeinab, et al.
Publicado: (2023) -
523. Dual vs. Triple Antibiotic Therapy for Carbapenem-Resistant Acinetobacter baumannii Infections
por: Markelwith, Justin Patrick, et al.
Publicado: (2019)